Subsequently, the released Zn2+ could not only trigger the decrease of NAD+ and the inactivation of GAPDH to achieve effective glycolysis inhibition but also active GD to downregulate the expression of GLUT1, which was beneficial to inhibiting the glycolysis process and achieving energy exhaustion in the tumor sites, providing a new paradigm for MOF-based nanocarrier to inhibit tumor growth via starvation therapy. The gene discussed is SLC2A1; the disease is neoplasm.